Joshua Ofman Sells 6,114 Shares of GRAIL (NASDAQ:GRAL) Stock

GRAIL, Inc. (NASDAQ:GRAL) President Joshua Ofman sold 6,114 shares of GRAIL stock in a transaction that occurred on Thursday, October 16th. The shares were sold at an average price of $82.01, for a total transaction of $501,409.14. Following the completion of the transaction, the president directly owned 381,818 shares in the company, valued at approximately $31,312,894.18. This represents a 1.58% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

GRAIL Stock Down 9.7%

NASDAQ:GRAL opened at $78.00 on Friday. GRAIL, Inc. has a 12 month low of $12.76 and a 12 month high of $89.57. The firm has a market cap of $2.81 billion, a price-to-earnings ratio of -5.95 and a beta of 4.11. The company’s 50 day moving average is $46.19 and its 200-day moving average is $40.09.

GRAIL (NASDAQ:GRAL) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($3.18) EPS for the quarter, missing analysts’ consensus estimates of ($3.14) by ($0.04). GRAIL had a negative net margin of 329.86% and a negative return on equity of 16.64%. The firm had revenue of $35.54 million during the quarter, compared to the consensus estimate of $37.57 million. Research analysts predict that GRAIL, Inc. will post -15.15 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on GRAL shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of GRAIL in a research report on Wednesday, October 8th. UBS Group set a $75.00 target price on shares of GRAIL in a research report on Friday, October 3rd. Finally, Canaccord Genuity Group boosted their target price on shares of GRAIL from $43.00 to $75.00 and gave the stock a “buy” rating in a research report on Friday, October 3rd. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, GRAIL currently has an average rating of “Hold” and an average target price of $56.67.

Institutional Investors Weigh In On GRAIL

Several institutional investors and hedge funds have recently bought and sold shares of GRAL. GAMMA Investing LLC increased its holdings in GRAIL by 4,102.5% in the 1st quarter. GAMMA Investing LLC now owns 25,131 shares of the company’s stock valued at $642,000 after buying an additional 24,533 shares during the period. Wealth Enhancement Advisory Services LLC bought a new stake in GRAIL in the 1st quarter valued at $719,000. Oppenheimer & Co. Inc. increased its holdings in GRAIL by 19.9% in the 1st quarter. Oppenheimer & Co. Inc. now owns 12,794 shares of the company’s stock valued at $327,000 after buying an additional 2,125 shares during the period. S.A. Mason LLC increased its holdings in GRAIL by 50.1% in the 1st quarter. S.A. Mason LLC now owns 1,499 shares of the company’s stock valued at $38,000 after buying an additional 500 shares during the period. Finally, Wealthquest Corp bought a new stake in GRAIL in the 1st quarter valued at $18,247,000.

GRAIL Company Profile

GRAIL, Inc operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T.